Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) comes with a set of practical rules that genuinely matter for how well it works and how comfortable the experience is. The most important do's and don'ts on Mounjaro aren't complicated, but they're easy to miss in a long patient leaflet. This is a prescription-only medicine; a GPhC-registered prescriber assesses your suitability before any treatment begins, and the advice here complements (never replaces) that clinical relationship. If you have specific questions about your own situation, the contact page reaches our aftercare team seven days a week.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misconception our prescribers encounter is that Mounjaro does all the heavy lifting and diet or activity choices become irrelevant. That's not what the licence or the trial evidence show. Tirzepatide is licensed alongside a reduced-calorie diet and increased physical activity, not as a substitute for them. The SURMOUNT-1 trial, which involved around 2,500 adults with obesity over 72 weeks, paired the medicine with regular dietary and lifestyle coaching throughout. The results (average body-weight reductions of around 20–21% at the highest dose) reflected that combined effort.
This isn't a lecture. If you're reading this you've probably already spent years trying approaches that didn't stick, and that's a genuinely exhausting place to be. The point isn't that you need to be perfect; it's that small, consistent shifts (eating more slowly, prioritising protein and vegetables, moving more on most days) work with what the medicine is already doing to slow gastric emptying and reduce appetite. Ignoring them doesn't mean treatment fails, but it does mean leaving a significant part of the benefit on the table. Our weight-loss treatment overview explains how the medicines fit into a broader plan.
The practical do that follows from this: treat the appetite suppression as an opportunity to build habits, not just a passive experience. The don't: assume that because you feel less hungry, what you eat no longer matters.
Mounjaro is a once-weekly subcutaneous injection. Rotate your injection site each week between the abdomen, upper thigh and outer upper arm; using the same patch of skin repeatedly increases the chance of localised lumps or reactions. Administer at roughly the same time each week, it doesn't have to be exact to the minute, but consistency helps.
Alcohol is worth approaching carefully, particularly in the early weeks. Mounjaro can lower blood pressure slightly and also causes some people to feel the effects of alcohol more intensely than usual; it isn't prohibited, but heavy drinking is a don't on any weight-management programme, and it interacts poorly with the nausea that some people feel after a dose increase. Our Mounjaro dos and don'ts guide covers these practical considerations in more detail, including how to manage common triggers around dose day.
Keep the pen refrigerated between 2°C and 8°C; the exact room-temperature storage window is detailed in the Patient Information Leaflet that comes with your medicine, the tirzepatide information page explains what to look for, but always defer to the leaflet supplied with your specific pen rather than any general figure online. If you are using the higher-concentration format, our tirzepatide 4ml page covers the specific handling and dosing details for that pen.
Tell every healthcare professional you see (GP, dentist, surgeon, anaesthetist) that you take tirzepatide. This matters most before any procedure involving sedation or general anaesthesia. NHS England's guidance on weight-management injections includes specific pre-surgical advice around GLP-1 and dual-agonist medicines.
Tirzepatide slows gastric emptying. For most medicines that's not clinically significant, but for oral tablets whose absorption depends on how quickly they move through the stomach, it can matter. The oral contraceptive pill is the clearest example. UK guidance is specific: add a non-oral contraceptive method (condoms, for instance) for the first four weeks of treatment and for four weeks after each dose increase. This isn't a rare edge case; it applies to anyone on the pill starting or stepping up their dose.
Women taking HRT in tablet form may also want to discuss whether a transdermal option (patch or gel) would be more appropriate while on tirzepatide, for the same reason. NHS England raises this explicitly in its patient-facing guidance. The conversation belongs with your prescriber at or before your next dose review, if you're a nume patient, our FAQs cover how to raise questions between reviews.
The don't here is assuming other long-term oral medicines are unaffected without checking. If you're on anticoagulants, thyroid medication or any drug with a narrow therapeutic window, your prescriber needs to know you're starting tirzepatide. This is the kind of nuance a clinician-led service is specifically built to assess.
Most side effects on Mounjaro are gastrointestinal and most settle down within a few days to a couple of weeks, nausea, loose stools, constipation and indigestion are common, particularly after starting or increasing a dose. These are uncomfortable, not dangerous, and gentle measures (smaller meals, staying hydrated, taking it slowly with fatty or spicy food) usually help. Some patients also ask about other health areas affected by treatment, and if that includes questions about sexual function, our page on Mounjaro and ED addresses what the evidence currently shows.
Certain symptoms require prompt medical attention. Severe stomach pain that doesn't ease (especially if it radiates to the back, or comes with persistent vomiting) may indicate pancreatitis. In January 2026 the MHRA issued a formal Drug Safety Update drawing attention to this risk across GLP-1 medicines; you can report suspected side effects directly via the MHRA Yellow Card scheme. Don't wait to see if severe pain resolves on its own; go to A&E or call 111.
Signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat) and significant dehydration from prolonged vomiting or diarrhoea also warrant urgent care. If you're a nume patient and something feels off but doesn't rise to emergency level, our aftercare team is reachable seven days a week. For a broader look at how the Mounjaro treatment page describes the medicine and its monitoring, that's a natural next read.
If you'd like a prescriber to review whether Mounjaro is right for you, speak to our prescribers through a free consultation, assessed the same day, with no waiting list. We also offer in-person support if you prefer to be seen face to face, and our Mounjaro London clinic page has details on appointments and locations available in the capital.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.